Keyword Analysis & Research: dicerna
Keyword Research: People who searched dicerna also searched
Search Results related to dicerna on Search Engine
-
Dicerna Pharmaceuticals Corporate Website | Dicerna …
http://dicerna.com/
webDicerna.com adalah perusahaan biopharmasi yang menggunakan interferensi RNA, atau RNAi, untuk menciptakan obat-obatan yang menutup gen-gen yang menyebabkan atau berkontribusi pada penyakit langka atau umum. Pelajari lebih lanjut tentang visi, misi, dan nilai-nilai kami di situs web kami.
DA: 64 PA: 65 MOZ Rank: 70
-
Novo Nordisk to Acquire Dicerna | Business Wire
https://www.businesswire.com/news/home/20211118005644/en/Novo-Nordisk-to-Acquire-Dicerna
webNov 18, 2021 · LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will...
DA: 5 PA: 89 MOZ Rank: 79
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435
webNov 18, 2021 · Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform. Bagsværd, Denmark, 18 November 2021 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference …
DA: 41 PA: 23 MOZ Rank: 40
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers ... - Business …
https://www.businesswire.com/news/home/20210330005357/en/Dicerna%E2%80%99s-GalXC-Plus%E2%84%A2-RNAi-Technology-Delivers-Target-Knockdown-Across-CNS-and-to-Specific-CNS-Cell-Types-in-Preclinical-Studies
webMar 30, 2021 · Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies. LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Dicerna Pharmaceuticals...
DA: 66 PA: 15 MOZ Rank: 19
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=93736
webBagsværd, Denmark, 28 December 2021 – Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a ...
DA: 1 PA: 88 MOZ Rank: 79
-
Dicerna Pharmaceuticals, Inc. | LinkedIn
https://www.linkedin.com/company/dicerna-pharmaceuticals-inc./
web1,761 36 Comments. Dicerna Pharmaceuticals, Inc. | 30,568 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid...
DA: 63 PA: 61 MOZ Rank: 99
-
Novo to acquire Dicerna for more than $3B amid RNA drug …
https://www.biopharmadive.com/news/novo-dicerna-rnai-acquire-deal/610254/
webNov 18, 2021 · Novo will pay $38.25 per share in cash for Dicerna, an 80% premium to the $21.28 closing price of the biotech’s shares Wednesday — the third-highest premium in a deal for a publicly traded biotech this year, according to BioPharma Dive’s database.
DA: 62 PA: 80 MOZ Rank: 91
-
Dicerna Presents Data From Phase 1 Trial of Belcesiran at …
https://www.businesswire.com/news/home/20211112005405/en/Dicerna-Presents-Data-From-Phase-1-Trial-of-Belcesiran-at-American-Association-for-the-Study-of-Liver-Diseases-AASLD-The-Liver-Meeting%C2%AE-2021
webNov 12, 2021 · LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented ...
DA: 71 PA: 54 MOZ Rank: 31
-
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need …
https://finance.yahoo.com/news/novo-nordisk-swallows-dicerna-3-142816889.html
webNov 18, 2021 · Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% ...
DA: 56 PA: 75 MOZ Rank: 52
-
Novo Nordisk to acquire biopharmaceutical company Dicerna for …
https://www.pharmaceutical-technology.com/news/novo-nordisk-acquire-dicerna/
webNov 19, 2021 · Novo Nordisk has signed a definitive agreement for the acquisition of Dicerna Pharmaceuticals, including its ribonucleic acid interference (RNAi) platform, for a total equity price of nearly $3.3bn in cash.
DA: 46 PA: 11 MOZ Rank: 41